Are you Dr. Coughlin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 45 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
34th & Civic Center Blvd
Children's Hospital Of Philadelphia
Philadelphia, PA 19104Phone+1 215-590-1000Fax+1 215-561-0959
Summary
- Dr. Christina Coughlin, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2001 - 2004- Children's Hospital of PhiladelphiaResidency, Pediatrics, 1999 - 2001
Perelman School of Medicine at the University of PennsylvaniaClass of 1999
Certifications & Licensure
PA State Medical License 2001 - 2014
Clinical Trials
- RTX-240 Monotherapy and in Combination With Pembrolizumab Start of enrollment: 2020 May 06
Publications & Presentations
PubMed
- 47 citationsA First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid TumorsLuis A. Diaz, Christina M. Coughlin, Susan C. Weil, Jean Fishel, Mrinal M. Gounder
Clinical Cancer Research. 2015-03-15 - 251 citationsTumor Cell Responses to IFNγ Affect Tumorigenicity and Response to IL-12 Therapy and AntiangiogenesisChristina M. Coughlin, Kevin E. Salhany, Michael S. Gee, Denise C. LaTemple, Serguei V. Kotenko
Immunity. 1998-07-01 - 346 citationsInterleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis.Christina M. Coughlin, Kevin E. Salhany, Maria Wysocka, Etsuko Aruga, Holly L. Kurzawa
The Journal of Clinical Investigation. 1998-03-15
Press Mentions
- CytoImmune Therapeutics Appoints Remus Vezan, M.D., Ph.D., as Chief Medical OfficerSeptember 7th, 2022
- CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatments for Both Solid Tumors and Hematologic MalignanciesMarch 8th, 2022
- City of Hope and CytoImmune Announce Study Demonstrating Novel Off-the-Shelf Chimeric Antigen Receptor (CAR) Natural Killer (NK) Cell-Based Therapy Against Pancreatic CancerJanuary 18th, 2022
- Join now to see all
